

## ATTORNEYS AT LAW

WASHINGTON HARBOUR 3000 K STREET, N.W. SUITE 600 WASHINGTON, D.C. 20007-5109 202.672.5390 TEL 202.672.5399 FAX WWW.FOLEY.COM

WRITER'S DIRECT LINE 202.672.5430 drosen@foley.com EMAIL

October 22, 2019

## VIA ELECTRONIC SUBMISSION

Division of Dockets Management (HFA-305) Food and Drug Administration Department of Health and Human Services 5360 Fishers Lane, Room 1061 Rockville, MD 20852

Re: Withdrawal of Petition; Docket No. FDA-2019-P-4507

Dear Sir or Madam:

Petitioner requests withdrawal of the above-referenced citizen petition requesting to designate an additional Reference Standard (RS) status for Oxybutynin Chloride Extended Release Tablets 15 mg, specifically the ANDA held by Accord Healthcare Inc. (ANDA No. 207138). FDA has already designated this product as the RS for the above mentioned product. Consequently, a formal response to Docket No. FDA-2019-P-4507 is no longer necessary.

Sincerely yours,

David L. Rosen, B.S. Pharm., JD